ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 730

Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association

Nicolai Leuchten1, Barbara Milke1, Borgi Winker-Rohlfing2, David I. Daikh3, Thomas Dorner4, Sindhu R. Johnson5, Martin Aringer1 and on behalf of the SLE Classification Criteria Steering Committee, 1Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, 2Lupus Erythematodes Selbsthilfegemeinschaft e.V., Wuppertal, Germany, 3Rheumatology, UCSF/VA Medical Center, San Francisco, CA, 4Charité University Medicine Berlin, Berlin, Germany, 5Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: classification criteria and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: EULAR and ACR have jointly funded a project to develop systemic lupus erythematosus (SLE) classification criteria, aiming at earlier and more accurate classification of the disease. This abstract reports on an early phase of that project, aimed at collecting potential candidate criteria. The objective of this study was to identify early symptoms of SLE from the patient perspective. Since SLE patients usually experience the onset and diagnosis as a critical life event, memories of this time appear remarkably accurate.   

Methods: As approved by the local ethics committee, we conducted a cross-sectional survey of German SLE patients. An anonymous self-report questionnaire was published in the “Schmetterling” the quarterly journal of the “Lupus erythematodes Selbsthilfegemeinschaft”, the German SLE patient association. Patients were asked for year of and age at their initial diagnosis. The questionnaire included typical organ manifestations, symptoms and autoantibodies. In addition, patients were asked to add additional symptoms in free text. For each symptom, boxes were provided to indicate the presence of the symptom before diagnosis, in the first year of diagnosis and at the time of completion of the questionnaire.

Results: 300 patient questionnaires were completed and mailed. Of the respondents, 93% were female, their mean age at diagnosis was 36 years, their mean disease duration was 17 years, 82% reported to definitely be ANA-positive. Joint, skin and kidney involvement were reported at 82%, 65% and 34%, respectively. 22% of patients reported fibromyalgia. For the time before and shortly after diagnosis, more than 50% of the patients reported fatigue (90%), joint pain (87%), hypersensitivity to sunlight (79%), myalgias (77%), skin rashes (71%), fever (53%), hair loss (51%) and Raynaud’s (50%). Approximately one third (35%) affirmed shortness of breath. Free text symptoms reported frequently before or early in diagnosis are listed in Table 1.

Table 1: Symptoms added in free text by at least 10 patients for the time before or shortly after the SLE diagnosis

 

n   (    %)

Diarrheas/abdominal pain

32 (11%)

Headache/migraine

31 (10%)

Sicca symptoms

30 (10%)

Depression/mood disorder

25 (  8%)

Cognitive impairment

23 (  8%)

Dizziness/vertigo

18 (  6%)

Polyneuropathy/paresthesias

15 (  5%)

Sleep disturbance

12 (  4%)

Conclusion: For a Caucasian European SLE patient population, the overall characteristics suggested meaningful representation. While many symptoms were reported as expected, a significant number of patients volunteered gastrointestinal complaints and symptoms of the central and peripheral nervous system. These data add to the information on early SLE symptoms that may be relevant for distinguishing early SLE from other diseases.


Disclosure: N. Leuchten, None; B. Milke, None; B. Winker-Rohlfing, None; D. I. Daikh, None; T. Dorner, None; S. R. Johnson, None; M. Aringer, None.

To cite this abstract in AMA style:

Leuchten N, Milke B, Winker-Rohlfing B, Daikh DI, Dorner T, Johnson SR, Aringer M. Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/early-symptoms-of-systemic-lupus-erythematosus-as-reported-by-members-of-the-german-lupus-erythematosus-patient-association/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-symptoms-of-systemic-lupus-erythematosus-as-reported-by-members-of-the-german-lupus-erythematosus-patient-association/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology